Surcel, H.M., Syrjala, H., Karttunen, R., Tapaninaho, S. and Herva, E. (1991) Development of Francisella tularensis Antigen Responses Measured as T-lymphocyte Proliferation and Cytokine Production (Tumor Necrosis Factor Alpha, Gamma Interferon, and Interleukin-2 and -4) during Human Tularemia. Infection and Immunity, 59, 1948-1953.

has been cited by the following article:

• TITLE: Vaccination with the Live Attenuated Francisella novicida Mutant FTN0109 Protects against Pulmonary Tularemia

  AUTHORS: Aimee L. Cunningham, M. Neal Guentzel, Jieh-Juen Yu, Nikita Trivedi, Karl E. Klose, James P. Chambers, Bernard P. Arulanandam

  KEYWORDS: Tularemia, F. tularensis, Vaccines, Live Attenuated

  JOURNAL NAME: World Journal of Vaccines, Vol.5 No.1, January 20, 2015

  ABSTRACT: Francisella tularensis is considered a potential bioterrorism agent due to its low infectious dose, high mortality rate, and ability to be spread via the aerosol route. We characterized the F. tularensis subspecies novicida mutant strain FTN0109 as a potential vaccine candidate against tularemia. This strain, which lacks an outer membrane lipoprotein, is attenuated in vitro and in vivo, as it exhibits reduced replication within murine J774 macrophages and has a pulmonary LD50 in BALB/c and C57BL/6 mice of >105 CFU (compared to WT parental strain U112, LD50 FTN0109 also conferred complete protection in BALB/c mice against subsequent pulmonary challenge with 10 LD50 (60,000 CFU) of the murine virulent Francisella strain LVS. We also have demonstrated partial protection (50%) against the highly human virulent subspecies tularensis strain SCHU S4 (25 LD50, 12,500 CFU) following intratracheal vaccination in the Fischer 344 rat, a second rodent model for tularemia. Overall, our results suggest that FTN0109 serves as a potential putative vaccine candidate against pulmonary tularemia.